

August 5, 2026

To

BSE Limited,

Listing Department, P J Towers,
Dalal Street,
Mumbai – 400 001.

National Stock Exchange of India Limited,

Listing Department, "Exchange Plaza",
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Scrip Code: 540679

Trading Symbol: HALEOSLABS

SUB: UPDATE ON MATERIAL SUBSIDIARY.

Ref: Reg. 30 (9) of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015.

Dear Sir/Madam,

With reference to the above-cited subject, we hereby inform you that the Board of Directors of M/s Mahi Drugs Private Limited, a material subsidiary of the Company, at its meeting held today, i.e., August 5, 2026, has, inter alia, approved the following:

1) Appointment of Cost Auditors for the year 2026-27.

Annapragada & Co. (firm resignation no. 006031) appointed as Cost Auditors of the Subsidiary Company for the year 2026-27 pursuant to the provisions of Section 148 of the Companies Act, 2013 read with Rule 14 and other applicable rules of the Companies (Audit and Auditors) Rules, 2014.

2) Appointment of Nominee Director.


Mr. Vincent P. Asaro (DIN: 11827706) have been appointed as the Nominee Director of Subsidiary Company as nominated by ChemWerth Inc., w.e.f. August 5, 2026, in place of Mr. M. Madhu Rao, who shall cease to be Nominee Director of the Subsidiary Company with effect from the same date.

The above information is also available on the website of the Company www.haleoslabs.com

Please take the same on record and suitably disseminate to all concerned.

For Haleos Labs Limited

(Formerly known as "SMS Lifesciences India Limited")


Trupti Ranjan Mohanty

Company Secretary



Haleos Labs Limited

(Formerly SMS Lifesciences India Limited)

☐ **Appointment of Cost Auditors:**

Particulars	Information
Name of the Auditor and Firm	Annapragada & Co.
Registration Number (FRN)	(Formerly known as Harshitha Annapragada & Co.) (FRN: 0060311)
Reason for change (reappointment)	Appointed as Cost Auditors of the Company.
Date of reappointment & term of reappointment	Appointed for the financial year 2026-27. Appointment in the Board Meeting held on 05.08.2026 and the remuneration shall be subject to ratification of shareholders in the next Annual General Meeting.
Brief Profile	Annapragada & Co. (Formerly known as "Harshitha Annapragada & Co."), is a firm of Cost Accountants with good analytical and results driven with good experience in developing and implementing cost account system and analysing cost trends. The firm has experience in the field of Cost Audits, Finance, Forecasting and process improvement. Dedicated Cost Accountant with good experience providing accounting support to various operating groups and manufacturing plants. Good knowledge of relevant government regulations, internal controls, cost accounting methods, and cost modelling tools and other methods.
Disclosure of Relationship between Directors	Not Applicable

☐ **Appointment of Nominee Director:**

Particulars	Information
Name of the Director	Mr. Vincent P. Asaro
Director Identification Number (DIN)	11827706
Nationality	US Citizen
Education	Mr. Asaro is a Certified Public Accountant (CPA) and holds an MBA in Finance from the University of Connecticut and a Bachelor of Science in Accounting from Providence College. He has also completed executive education at Harvard Business School. Recognized for his strategic leadership and financial acumen, he is committed to advancing innovation, expanding global partnerships, and strengthening pharmaceutical supply chains to support the development and commercialization of high-quality generic APIs.
Working Experience	He is the President of ChemWerth Inc., a leading global developer and supplier of Active Pharmaceutical Ingredients (APIs) to regulated pharmaceutical markets worldwide. With over 35 years of experience in finance, corporate strategy, business development, and pharmaceutical operations, he has played a pivotal role in driving ChemWerth's growth and strengthening its global presence. Prior to his appointment as President, Mr. Asaro served as the Chief Financial Officer of ChemWerth Inc. since 2009, where he led the company's financial strategy, operational excellence, and business expansion initiatives. Earlier in his career, he held finance and leadership positions with Deloitte & Touche and Bayer, gaining extensive expertise in accounting, auditing, internal controls, and corporate finance. He also serves on the Board of Directors of Bedoukian Research, Inc.
Relationship between Directors Inter-se	Not Applicable

